Dasatinib therapy can result in significant pulmonary toxicity

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|12|E224-E225

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.12, 2015-12, pp. : E224-E225

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy

By  

Acta Haematologica, Vol. 118, Iss. 3, 2007-09 ,pp. : 162-164

Karger

Access to resources Recommend Favorite

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 1060-1064

John Wiley & Sons Inc

Access to resources Recommend Favorite

Unsuccessful Dasatinib Therapy in a Refractory Patient with Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 124, Iss. 2, 2010-08 ,pp. : 103-104

Karger

Access to resources Recommend Favorite

Exercise programme to reduce treatment toxicity when initiating ADT

By  

BJU INTERNATIONAL, Vol. 115, Iss. 2, 2015-02 ,pp. : 256-266

John Wiley & Sons Inc

Access to resources Recommend Favorite

Can Pulmonary Vascular Resistance Predict Response to Cardiac Resynchronization Therapy in Patients with Heart Failure?

By  

PACING AND CLINICAL ELECTROPHYSIOLOGY, Vol. 38, Iss. 10, 2015-10 ,pp. : 1210-1216

John Wiley & Sons Inc

Access to resources Recommend Favorite